Sofosbuvir for previously untreated chronic hepatitis C infection
Abstract
In a single-group study of sofosbuvir combined with peginterferon-ribavirin, patients with predominantly genotype 1 or 4 HCV infection had a rate of sustained virologic response of 90% at 12 weeks. In a noninferiority trial, patients with genotype 2 or 3 infection who received either sofosbuvir or p …
Keywords
hepatitis c
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
RNA
humans
pubmed abstract
nih
national institutes of health
national library of medicine
logistic models
research support
non-u.s. gov't
adult
female
male
aged
middle aged
young adult
Clinical Trial
Phase III
Randomized Controlled Trial
Multicenter Study
Genotype
viral / blood
drug therapy
combination
antiviral agents / therapeutic use*
ribavirin / therapeutic use*
recombinant proteins / adverse effects
recombinant proteins / therapeutic use
chronic / virology
antiviral agents / adverse effects
hepacivirus / genetics*
chronic / drug therapy*
interferon-alpha / adverse effects
interferon-alpha / therapeutic use*
polyethylene glycols / adverse effects
polyethylene glycols / therapeutic use*
ribavirin / adverse effects
eric lawitz
alessandra mangia
liver cirrhosis / virology
sofosbuvir
uridine monophosphate / analogs & derivatives*
uridine monophosphate / therapeutic use
pmid:23607594
doi:10.1056/nejmoa1214853
edward j gane
uridine monophosphate / adverse effects
Access
Citation
ID:
273565
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
273565
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet